Loading...
•
Jun 30, 2022
Eagle Q2 2022 Earnings Report
Reported financial results for the three months ended June 30, 2022.
Key Takeaways
Eagle Pharmaceuticals reported a strong second quarter in 2022, with total revenue of $74.1 million compared to $48.1 million in Q2 2021. The company's adjusted non-GAAP earnings per basic share for the first half of 2022 more than doubled compared to the full year 2021, marking the best earnings performance in the company's history.
Net loss was $(0.74) per basic and diluted share, while adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share.
Total revenue reached $74.1 million, driven by product sales of vasopressin and PEMFEXY®.
First half revenue of $190 million exceeded full year 2021 revenue of $171.5 million.
Acquired Acacia Pharma Group plc, adding BARHEMSYS® and BYFAVO® to portfolio.